Immune reactivity of sera obtained from brucellosis patients and vaccinated-rabbits to a fusion protein from Brucella melitensis

Document Type: Original Article


1 Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

3 Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran


Objective(s): Brucella spp. are facultative intracellular pathogens which can stay alive and multiply in professional and nonprofessional phagocytes. Immunity against Brucella melitensis involves antigen-specific CD4+ and CD8+ T-cells activation and humoral immune responses. Due to negative aspects of live attenuated vaccines, much attention has been focused on finding Brucella-protective antigens to introduce them as potential subunit vaccine candidates.
Materials and Methods: A chimeric gene encoding trigger factor (TF), Omp3148-74 and BP2687-111 fragments (TOB) from B. melitensis was successfully cloned, expressed in Escherichia coliBL21-DE3 and purified by Ni-NTA agarose column. Antibodies to recombinant TOB (rTOB) have been investigated in Brucella-infected human sera and a pool serum prepared from B. melitensis-vaccinated rabbits.
Results: Our results showed that the immunized rabbit pool serum strongly reacted with rTOB. In addition, antibodies against rTOB were detectable in 76.5% of sera obtained from infected patients.
Conclusion: These findings suggest that rTOB may provide a potential immunogenic candidate which could be considered in future vaccine studies.


1. Liang L, Leng D, Burk C, Nakajima-Sasaki R, Kayala MA, Atluri VL, et al. Large scale immune profiling of infected humans and goats reveals differential recognition of Brucella melitensis antigens. PLoS Negl Trop Dis 2010;4:e673.

2. Jain-Gupta N, Contreras-Rodriguez A, Smith GP, Garg VK, Witonsky SG, Isloor S, et al. Immuno-therapeutics to prevent the replication of Brucella in a treatment failure mouse model. Vaccine 2014;32:918-923.

3. Sanakkayala N, Sokolovska A, Gulani J, Hogenesch H, Sriranganathan N, Boyle SM, et al. Induction of antigen-specific Th1-type immune responses by gamma-irradiated recombinant Brucella abortus RB51. Clin Diagn Lab Immunol 2005;12:1429-1436.

4. Avila-Calderon ED, Lopez-Merino A, Sriranganathan N, Boyle SM, Contreras-Rodriguez A. A history of the development of Brucella vaccines. Biomed Res Int 2013;2013:743509.

5. Gomez G, Adams LG, Rice-Ficht A, Ficht TA. Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis. Front Cell Infect Microbiol 2013;3:17.

6. Durward MA, Harms J, Magnani DM, Eskra L, Splitter GA. Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo. Infect Immun 2010;78:168-176.

7. Vitry MA, De Trez C, Goriely S, Dumoutier L, Akira S, Ryffel B, et al. Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun 2012;80:4271-4280.

8. Cannella AP, Tsolis RM, Liang L, Felgner PL, Saito M, Sette A, et al. Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development. Front Cell Infect Microbiol 2012;2:1.

9. Al-Mariri A. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine 2010;28:1766-1770.

10. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, de la Barrera S, et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 2007;25:4437-4446.

11. Yang X, Hudson M, Walters N, Bargatze RF, Pascual DW. Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun 2005;73:7297-7303.

12. Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, et al. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK). Infect Immun 1999;67:5877-5884.

13. Letesson JJ, Tibor A, van Eynde G, Wansard V, Weynants V, Denoel P, et al. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1997;4:556-564.

14. Ferbitz L, Maier T, Patzelt H, Bukau B, Deuerling E, Ban N. Trigger factor in complex with the ribosome forms a molecular cradle for nascent proteins. Nature 2004;431:590-596.

15. Ghasemi A, Salari MH, Zarnani AH, Pourmand MR, Ahmadi H, Shirazi MH, et al. Immunogenicity assessment of Brucella mellitensis HSP and TF proteins by immunized rabbit serum. Iran J Allergy Asthma Immunol 2013;12:192-194.

16. Ghasemi A, Salari MH, Zarnani AH, Pourmand MR, Ahmadi H, Mirshafiey A, et al. Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins. Iran JMicrobiol 2013;5:19-23.

17. Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clin Diagn Lab Immunol 2004;11:111-114.

18. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 2005;73:8079-8088.

19. Liu WX, Hu S, Qiao ZJ, Chen WY, Liu LT, Wang FK, et al. Expression, purification, and improved antigenic specificity of a truncated recombinant bp26 protein of Brucella melitensis M5-90: a potential antigen for differential serodiagnosis of brucellosis in sheep and goats. Biotechnol Appl Biochem 2011;58:32-38.

20. Qiu J, Wang W, Wu J, Zhang H, Wang Y, Qiao J, et al. Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies. PLoS One 2012;7:34246.

21. Ghasemi A, Ranjbar R, Amani J. In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multisubunit vaccine candidate. Iran J Basic Med Sci 2014;17:172-180.

22. Amani J, Mousavi SL, Rafati S, Salmanian AH. In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model 2009; 6:28.

23. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990;132:191-195.

24. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol 2000;76:97-119.

25. Stoscheck CM. Quantitation of protein. Methods Enzymol 1990;182:50-68.

26. Ghasemi A, Salari MH, Pourmand MR, Zarnani AH, Ahmadi H, Shirazi MH, et al. Optimization and Efficient Purification in production of Brucella melitensis recombinant HSP A and TF proteins with low endotoxin contents. Jundishapur J Microbiol 2013;6:e6875.

27. Ghasemi A, Zarnani AH, Ghoodjani A, Rezania S, Salari MH, Jeddi-Tehrani M. Identification of a new immunogenic candidate conferring protection against Brucella melitensis infection in Mice. Mol Immunol 2014;62:142-9.

28. Wang Z, Niu J, Wang S, Lv Y, Wu Q. In vivo differences in the virulence, pathogenicity, and induced protective immunity of wboA mutants from genetically different parent Brucella spp. Clin Vaccine Immunol 2013; 20:174-180.

29. Yang X, Skyberg JA, Cao L, Clapp B, Thornburg T, Pascual DW. Progress in vaccine development. Front Biol 2013;8:60-77.

30. Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X,
et al. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol 2011;49:175-184.

31. Wang W, Wu J, Qiao J, Weng Y, Zhang H, Liao Q,         et al. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep. Vaccine 2014;32:825-833.

32. Commander NJ, Spencer SA, Wren BW, MacMillan AP. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 2007;25:43-54.

33. Yang Y, Yin J, Guo D, Lang X, Wang X. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol Med Microbiol 2011;61:159-167.

34. Ghasemi A, Jeddi-Tehrani M, Mautner J, Salari MH, Zarnani AH. Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection. Vaccine 2014; 32:6659-6666.